Details
Rozucard Indications
- Treatment of hypercholesterolemia
- Primary hypercholesterolaemia (type IIa) or mixed dyslipidaemia (type IIb) as an adjunct to diet when diet and other non-pharmacological treatments (eg exercise, weight loss) are ineffective.
- Homozygous familial hypercholesterolemia. As an adjunct to diet and other therapeutic activities aimed at reducing the level of lipids (eg LDL apheresis), or when such treatments are not applied.
- Prevention of cardiovascular disorders
Rozukard shown to reduce the risk of serious cardiovascular events in adult patients with an increased risk of atherosclerotic cardiovascular disease, as evidenced by the presence of risk factors such as age, hypertension, low HDL cholesterol, elevated levels of CRP, smoking or the presence of family history of coronary artery disease early development.
Dosage & Administration
Before starting treatment the patient should be transferred to a standard diet, which reduces the level of cholesterol and to which he must adhere to during the entire treatment. The dose should be individualized depending on the purpose of therapy and the patient's response to treatment.
Rosuvastatin can be taken at any time of the day regardless of the meal.
Treatment of hypercholesterolemia
The recommended starting dose for patients previously treated with statin, or which is transferred to the reception of another HMG-CoA reductase inhibitor is 5 or 10 mg. The dose of 5 mg may be obtained by dividing the 10 mg tablet in half along the fault line.
Contradictions
- hypersensitivity to rosuvastatin or to any excipients;
- liver disease in its active phase, including unknown etiology persistent increase in transaminase levels and serum - transaminase level any more than 3 times the upper limit of normal;
- severe renal dysfunction (creatinine clearance <30 mL / min);
- myopathy;
- concomitant use of cyclosporine;
- pregnancy and breastfeeding.
A dose of 40 mg is contraindicated in patients with factors that contribute to the development of myopathy / rhabdomyolysis.
These factors include:
- renal moderate impairment (creatinine clearance <60 mL / min);
- hypothyroidism;
- the presence of an individual or family history of hereditary diseases of the musculoskeletal system;
- a history miotoksichnosti caused by other inhibitors of HMG-CoA reductase inhibitor or fibrate;
- alcohol abuse;
- situation that may lead to increased levels of drug in blood plasma;
- patients belonging to the representatives of the peoples of Asia;
- concurrent use of fibrates.
